Drug
SHR-4602
SHR-4602 is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Completion Rate
0%(0/1)
Active Trials
1(25%)
Terminated
1(25%)
Phase Distribution
Ph phase_2
3
75%
Ph phase_1
1
25%
Phase Distribution
1
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
3(75.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 2 finished
Non-Completion Rate
100.0%
2 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Terminated(2)
Detailed Status
Terminated1
Recruiting1
Withdrawn1
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
0.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (25.0%)
Phase 23 (75.0%)
Trials by Status
terminated125%
recruiting125%
withdrawn125%
not_yet_recruiting125%
Recent Activity
1 active trials
Showing 4 of 4
terminatedphase_2
SHR-4602 for Injection in Subjects With HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors
NCT06516926
recruitingphase_2
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
NCT05582499
withdrawnphase_1
A Trial of SHR-4602 Infusion in Patients With SHR-4602 in Subjects With HER2-expressing or HER2-mutated Locally Advanced or Metastatic Solid Tumors
NCT06560138
not_yet_recruitingphase_2
A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid Tumors
NCT06704828
Clinical Trials (4)
Showing 4 of 4 trials
NCT06516926Phase 2
SHR-4602 for Injection in Subjects With HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors
NCT05582499Phase 2
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
NCT06560138Phase 1
A Trial of SHR-4602 Infusion in Patients With SHR-4602 in Subjects With HER2-expressing or HER2-mutated Locally Advanced or Metastatic Solid Tumors
NCT06704828Phase 2
A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid Tumors
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4